• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

大鼠胰腺A 型胆囊收缩素受体拮抗剂结合位点的光亲和标记显示存在截短的A 型胆囊收缩素受体。

Photoaffinity labeling of rat pancreatic cholecystokinin type A receptor antagonist binding sites demonstrates the presence of a truncated cholecystokinin type A receptor.

作者信息

Poirot S S, Escrieut C, Dufresne M, Martinez J, Bouisson M, Vaysse N, Fourmy D

机构信息

Institut National de la Santé et de la Recherche Médicale, Centre Hospitalier Universitaire de Rangueil, Toulouse, France.

出版信息

Mol Pharmacol. 1994 Apr;45(4):599-607.

PMID:8183238
Abstract

During the past few years, several antagonist ligands for cholecystokinin (CCK) receptors have been discovered, but the mechanism of action of these candidate drugs, as well as the nature of their molecular targets, remains poorly documented. In a previous study, we developed a new antagonist radioligand, 125I-Bolton-Hunter-labeled JMV-179, for the CCK-A receptor (CCK-AR), to analyze CCK antagonist binding sites in pancreatic plasma membranes. We found that 125I-Bolton-Hunter-labeled JMV-179 identified 4 times as many sites as did an agonist radioligand, although agonists were able to interact competitively with the entire population of antagonist sites. In the present work, using biochemical approaches we have identified and characterized CCK antagonist binding sites in pancreatic plasma membranes. We synthesized the photoactivable antagonist probe 125I-azidosalicyclic acid (ASA)-JMV-179. The binding of 125I-ASA-JMV-179 to plasma membranes was inhibited by JMV-179 (IC50, 6 +/- 2 nM), by (Thr28, Ahx31)-CCK-25-33 (IC50, 1.2 +/- 0.5 nM), and by the nonpeptide CCK-AR antagonist L-364,718 (IC50, 2 +/- 1 nM). Photoaffinity labeling using pancreatic membranes or acini demonstrated that 125I-ASA-JMV-179 detected a new 47-50-kDa protein in addition to the 85-100-kDa CCK-AR. The 47-50-kDa protein was not directly detected by a photoactivable agonist, but agonists could inhibit its covalent labeling by 125I-ASA-JMV-179 (IC50 for (Thr28,Ahx31)-CCK-25-33, 15 nM). In competition assays using nonsolubilized or solubilized membranes, this protein displayed binding features of the CCK-AR and was retained on immobilized wheat germ agglutinin, as was the CCK-AR. To further characterize the 47-50-kDa protein, deglycosylation and protease digestions were performed, and the digestion products were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Protease digestions of both the CCK-AR and the 47-50-kDa protein yielded identical labeled fragments, demonstrating a structural relationship between the two proteins. The CCK-AR, which has three potential sites for N-glycosylation on the amino-terminal extracellular domain and one on the second extracytoplasmic loop, was deglycosylated to a 42-kDa peptide. The 47-50-kDa protein was deglycosylated to a 35-kDa peptide. These data, and the localization of the labeled fragments in the amino acid sequence of the receptor, suggest that the 47-50-kDa protein represents a CCK-AR lacking its amino-terminal extracellular domain.(ABSTRACT TRUNCATED AT 400 WORDS)

摘要

在过去几年中,已发现几种胆囊收缩素(CCK)受体的拮抗剂配体,但这些候选药物的作用机制及其分子靶点的性质仍记录不足。在先前的一项研究中,我们开发了一种用于CCK-A受体(CCK-AR)的新型拮抗剂放射性配体,即125I-博尔顿-亨特标记的JMV-179,以分析胰腺质膜中的CCK拮抗剂结合位点。我们发现,125I-博尔顿-亨特标记的JMV-179识别出的位点数量是激动剂放射性配体的4倍,尽管激动剂能够与全部拮抗剂位点竞争性相互作用。在本研究中,我们使用生化方法鉴定并表征了胰腺质膜中的CCK拮抗剂结合位点。我们合成了可光活化的拮抗剂探针125I-叠氮水杨酸(ASA)-JMV-179。JMV-179(IC50,6±2 nM)、(Thr28,Ahx31)-CCK-25-33(IC50,1.2±0.5 nM)和非肽CCK-AR拮抗剂L-364,718(IC50,2±1 nM)均可抑制125I-ASA-JMV-179与质膜的结合。使用胰腺膜或腺泡进行的光亲和标记表明,125I-ASA-JMV-179除了检测到85-100 kDa的CCK-AR外,还检测到一种新的47-50 kDa蛋白。可光活化激动剂未直接检测到47-50 kDa蛋白,但激动剂可抑制其被125I-ASA-JMV-179共价标记((Thr28,Ahx31)-CCK-25-33的IC50为15 nM)。在使用未溶解或溶解膜的竞争试验中,该蛋白表现出CCK-AR的结合特征,并与CCK-AR一样保留在固定化麦胚凝集素上。为了进一步表征47-50 kDa蛋白,进行了去糖基化和蛋白酶消化,并通过十二烷基硫酸钠-聚丙烯酰胺凝胶电泳分离消化产物。CCK-AR和47-50 kDa蛋白的蛋白酶消化产生了相同的标记片段,表明这两种蛋白之间存在结构关系。CCK-AR在氨基末端细胞外结构域有三个潜在的N-糖基化位点,在第二个胞外环有一个,去糖基化后形成一个42 kDa的肽段。47-50 kDa蛋白去糖基化后形成一个35 kDa的肽段。这些数据以及标记片段在受体氨基酸序列中的定位表明,47-50 kDa蛋白代表一种缺少其氨基末端细胞外结构域的CCK-AR。(摘要截短至四百字)

相似文献

1
Photoaffinity labeling of rat pancreatic cholecystokinin type A receptor antagonist binding sites demonstrates the presence of a truncated cholecystokinin type A receptor.大鼠胰腺A 型胆囊收缩素受体拮抗剂结合位点的光亲和标记显示存在截短的A 型胆囊收缩素受体。
Mol Pharmacol. 1994 Apr;45(4):599-607.
2
Study of the states and populations of the rat pancreatic cholecystokinin receptor using the full peptide antagonist JMV 179.使用全肽拮抗剂JMV 179对大鼠胰腺胆囊收缩素受体的状态和数量进行研究。
Eur J Biochem. 1993 Mar 1;212(2):529-38. doi: 10.1111/j.1432-1033.1993.tb17690.x.
3
A new probe for affinity labelling pancreatic cholecystokinin receptor with minor modification of its structure.一种用于亲和标记胰腺胆囊收缩素受体的新型探针,其结构有微小修饰。
Eur J Biochem. 1989 Nov 6;185(2):397-403. doi: 10.1111/j.1432-1033.1989.tb15128.x.
4
Characterization of cholecystokinin receptors and messenger RNA expression in rat pancreas: evidence for expression of cholecystokinin-A receptors but not cholecystokinin-B (gastrin) receptors.大鼠胰腺中胆囊收缩素受体及信使核糖核酸表达的特征:胆囊收缩素-A受体而非胆囊收缩素-B(胃泌素)受体表达的证据
J Surg Res. 1995 Mar;58(3):281-9. doi: 10.1006/jsre.1995.1044.
5
Arginine 197 of the cholecystokinin-A receptor binding site interacts with the sulfate of the peptide agonist cholecystokinin.胆囊收缩素-A受体结合位点的精氨酸197与肽激动剂胆囊收缩素的硫酸盐相互作用。
Protein Sci. 1999 Nov;8(11):2347-54. doi: 10.1110/ps.8.11.2347.
6
A peptide agonist acts by occupation of a monomeric G protein-coupled receptor: dual sites of covalent attachment to domains near TM1 and TM7 of the same molecule make biologically significant domain-swapped dimerization unlikely.一种肽激动剂通过占据单体G蛋白偶联受体发挥作用:与同一分子中靠近跨膜区1(TM1)和跨膜区7(TM7)的结构域的两个共价连接位点使得具有生物学意义的结构域交换二聚化不太可能发生。
J Med Chem. 1999 Jun 17;42(12):2105-11. doi: 10.1021/jm980732q.
7
Cholecystokinin receptor characterization and cholecystokinin-A receptor messenger RNA expression in transgenic mouse pancreatic carcinomas and dysplastic pancreas.转基因小鼠胰腺癌和发育异常胰腺中胆囊收缩素受体的特性及胆囊收缩素-A 受体信使核糖核酸的表达
Oncol Res. 1994;6(9):411-7.
8
Distinct requirements for activation at CCK-A and CCK-B/gastrin receptors: studies with a C-terminal hydrazide analogue of cholecystokinin tetrapeptide (30-33).胆囊收缩素-A和胆囊收缩素-B/胃泌素受体激活的不同要求:用胆囊收缩素四肽(30-33)的C末端酰肼类似物进行的研究
Mol Pharmacol. 1989 Dec;36(6):881-6.
9
Differential expression of A- and B-subtypes of cholecystokinin/gastrin receptors in the developing calf pancreas.胆囊收缩素/胃泌素受体A-和B-亚型在发育中小牛胰腺中的差异表达。
Endocrinology. 1993 Sep;133(3):1182-91. doi: 10.1210/endo.133.3.8365360.
10
A new, highly selective CCK-B receptor radioligand ([3H][N-methyl-Nle28,31]CCK26-33): evidence for CCK-B receptor heterogeneity.一种新型高选择性CCK-B受体放射性配体([3H][N-甲基-Nle28,31]CCK26-33):CCK-B受体异质性的证据
J Pharmacol Exp Ther. 1990 Dec;255(3):1278-86.

引用本文的文献

1
CCK increases the transport of insulin into the brain.胆囊收缩素增加胰岛素向大脑的转运。
Physiol Behav. 2016 Oct 15;165:392-7. doi: 10.1016/j.physbeh.2016.08.025. Epub 2016 Aug 26.
2
Proliferative effects of cholecystokinin in GH3 pituitary cells mediated by CCK2 receptors and potentiated by insulin.胆囊收缩素通过CCK2受体介导并在胰岛素增强作用下对GH3垂体细胞产生增殖效应。
Br J Pharmacol. 1999 Jan;126(1):79-86. doi: 10.1038/sj.bjp.0702271.
3
Characterization and distribution of binding sites for a new neurotensin receptor antagonist ligand, [3H]SR 48692, in the guinea pig brain.
新型神经降压素受体拮抗剂配体[3H]SR 48692在豚鼠脑中结合位点的表征与分布
J Pharmacol Exp Ther. 1995 Jun;273(3):1450-8.